Amgen Inc. has announced the rapid acceleration of its clinical trial program for obesity, marking it as one of the largest in the company's 45-year history. The investigational medicine, maridebart cafraglutide, also known as MariTide, is at the center of the Phase 3 MARITIME program. This program aims to evaluate the safety and efficacy of MariTide for the treatment of obesity and obesity-related conditions. The MARITIME program includes MARITIME-1, a study focused on individuals with overweight or obesity, and MARITIME-2, which targets those living with type 2 diabetes and overweight or obesity. The results of these trials have not yet been presented. Further updates and information about the Phase 3 clinical program can be accessed through the MARITIME website.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.